Panadol-maker Haleon raises revenue forecast following high demand

Revenue should rise by  7% to 8% this year, Haleon said. The previous forecast was for growth of 4% to 6%

The consumer health business demerged from drug giant GSK last summer and is looking to sell some non-core brands and streamline its portfolio under CEO Brian McNamara. Picture: Dan Linehan

Haleon, which makes Panadol painkillers at its manufacturing facility in Waterford, lifted its revenue forecast following price increases.

The Sensodyne toothpaste maker also raised its full-year sales predictions after revenues rose 10% in the first six months as consumers stocked up on over-the-counter brands.